Drug Trial News

RSS

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

A protein that the body naturally produces could become an important new immunotherapy drug in the cache of cancer-fighting tools available to oncologists.

9 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Researchers plan to commence a clinical trial on new COVID-19 inactivated vaccine

A medical research team from the University of Hong Kong (HKU) will start a large-scale clinical trial on a new COVID-19 inactivated vaccine (Omicron variant) developed by China National Biotec Group (Sinopharm).

8 Jun 2022

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

In a recent phase III study published in the New England Journal of Medicine, researchers demonstrated that oral molnupiravir was effective in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapy among non-vaccinated, non-hospitalized adults at-risk for severe illness.

8 Jun 2022

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

In a recent investigation published in the Annals of Internal Medicine journal, scientists demonstrated the positive impacts of molnupiravir among severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients and the healthcare sector apart from lowering disease-linked deaths and hospitalizations in at-risk cohorts.

7 Jun 2022

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.

7 Jun 2022

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

6 Jun 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

A new clinical trial studying the effectiveness of a combination of immunotherapy treatments could be more effective for patients with ovarian cancer who are resistant to traditional interventions.

6 Jun 2022

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.

6 Jun 2022

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.

4 Jun 2022

$New combination of drugs increases survival time for some patients with refractory lung cancer$

New combination of drugs increases survival time for some patients with refractory lung cancer

A combination of the drugs ramucirumab and pembrolizumab reduced risk of death by 31% compared with the standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.

3 Jun 2022

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.

3 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Researchers receive $1.1 million to study the safety, efficacy of drug combination for chronic pancreatitis

Researchers from Indiana University School of Medicine are studying the safety and efficacy of a drug combination for patients with chronic pancreatitis (CP).

2 Jun 2022

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.

2 Jun 2022

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

Previous
1
...
45
46
47
48
49
50
51
...
1156
Next

Drug Trial News

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Researchers plan to commence a clinical trial on new COVID-19 inactivated vaccine

Molnupiravir reduces hospitalizations and deaths in at-risk, unvaccinated adults with COVID

Study finds added benefits of molnupiravir for non-hospitalized COVID-19 patients

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Promising results of combination treatment for acute myeloid leukemia to be presented at ASCO 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

Taking everolimus post-surgery can improve outcomes in patients with high-risk renal cell carcinoma

New combination of drugs increases survival time for some patients with refractory lung cancer

Study: Nearly 43% of patients with KRAS-mutated lung cancer respond to experimental drug adagrasib

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

Researchers receive $1.1 million to study the safety, efficacy of drug combination for chronic pancreatitis

NIH sponsors the trial of monoclonal antibody to prevent asthma exacerbations in urban youth

Newer class of antidiabetic drugs reduced risk of hospitalization for heart failure

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

Mucosal COVID vaccine candidate powerfully protective in macaques

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News